OPPI

Daily News Monitor

June 10, 2016

1. **Prescription habits predict compliance with breast cancer pills** – Reuters

   Lead author Dr. Alfred Neugut, of Columbia University Medical Center in New York City observes that the major problem in medicine in general is when people don't take their medication as prescribed. Interestingly, he and his colleagues wrote in JAMA Oncology that the problem, known as 'non-adherence', also extends to cancer medicines, even though they are generally viewed as life-saving or life-prolonging.

2. **Industry weighs radical shake-up of European drug pricing** – Reuters

   According to an internal report, the pharmaceutical industry in Europe is considering a radical shift in the way it prices drugs in Europe. As a result, companies are looking at a fundamentally different way of getting paid for their innovations. The report is the clearest sign yet that the drug industry is ready to negotiate a new pricing framework with governments and insurers.

3. **Reliance Lifesciences launches world's first biosimilar used to treat advanced cancers** – The Economic Times

   Reliance Lifesciences, the biopharmaceutical unit of Mukesh Ambani-led Reliance IndustriesBSE 1.81 %, has launched the world's first biosimilar, or copies of bevacizumab, a complex medicine used to treat at least six forms of advanced cancers. Reliance's product is approved by the Indian regulator for use in cases of colorectal cancer.

4. **Lupin recalls over 54,000 vials of anti-bacterial injection in US** – Mint

   Lupin has recalled over 54,000 vials of anti-bacterial injection, Ceftriaxone, due to violation of current manufacturing norms. The ongoing voluntary recall is a class-III recall for the US and Puerto Rico markets. The recall is being initiated by the company's US arm Lupin Pharmaceuticals Inc covering 54,472 vials of Ceftriaxone for injection in various strengths. The company is also recalling 741.171 kg of Ceftriaxone Sodium (Sterile) active pharmaceutical ingredient as its API intermediates failed specifications.

5. **Aspen Pharma acquires non-US rights of AstraZeneca's seven established drugs** – The Hindu Business Line
   South Africa's Aspen Pharmacare will market the seven established medicines outside the United States under the deal, which follows the sale of US rights to the anaesthetics 10 years ago to Abraxis, now part of Fresenius Kabi. Aspen will pay AstraZeneca $520 million upfront and up to $250 million in sales-related payments, as well as double-digit percentage trademark royalties, the companies said on Thursday. AstraZeneca has sold the marketing rights to a portfolio of anaesthetics for up to $770 million in the latest so-called externalisation deal to raise funds for investment in new drugs.

6. **Granules to sell 4 US pharma Windlas drugs in US** – The Financial Express
   Granules Pharmaceuticals Inc (GPI), the wholly-owned subsidiary of Granules India, has acquired the exclusive rights from USpharma Windlas, LLC to market and distribute four products in the US. US pharma Windlas, through its subsidiaries, holds Abbreviated New Drug Applications (ANDAs) for Fingolimod, Prasugrel, Dronedarone and Lurasidone. US pharma Windlas believes to be a first applicant to file ANDAs containing paragraph IV certifications for three of these products.

7. **Telemedicine takes healthcare to a new level** – The Hindu
   Already, telemedicine is vigorously practised in areas of ophthalmology, psychiatry and general medicine in the region with the sole objective of making quality healthcare accessible and affordable to all. Last week, on a single day, Aravind Eye Hospital screened over 850 patients, all of whom did not have to come to Madurai for an eye check-up. They were examined by ophthalmologists sitting at the base hospital. Telemedicine has come a long way and its applications have multiplied in the last few years. Madurai-based hardware companies have devised many useful tools that are used in hospitals all over the country. The growth

8. **Government mulls up to 49% Pharma FDI without prior approval** – The Times of India
   The government has kicked off consultations for a fresh round of liberalization of foreign direct investment (FDI) rules, with the finance ministry suggesting that up to 49% overseas flows be allowed in existing pharmaceutical companies via the automatic route. In addition, North Block has asked the department of industrial policy and promotion (DIPP) to identify other sectors where the norms can be eased, an exercise which has begun, sources told TOI. Finance ministry's proposal is in line with its stand of allowing more investments via the automatic route, which means that an investor only has to inform the RBI after pumping money into the country.

9. **Indian pharma leading global fight against HIV: Nadda at UNGA** – Hindustan Times
   Addressing the United Nations high level meeting, India's Health minister JP Nadda on Thursday said "More than 80 per cent of the low-cost drugs used to combat the HIV globally are manufactured in India and have helped scale up access to treatment across developing countries." The UN General Assembly adopted a new political declaration that recognises the "critical importance of affordable medicines, including generics, in scaling up access to affordable HIV treatment".

10. **OPPI facilitates a panel discussion on National IPR Policy** – Express Pharma
    As part of its Golden Jubilee Celebration and in line with the theme of 'Healthy India, Innovative India', the Organisation of Pharmaceutical Producers of India (OPPI) facilitated a discussion on the recently announced IPR Policy, specifically for the media. The discussion focused on interpreting the role of the policy in fostering a culture of innovation. Experts on the panel opined that the key to the success of the policy lies in its effective enforcement and implementation. The discussion covered several important aspects of the policy such as its practical impact, generation of knowledge capital and the need for specialised patent courts to hear patent cases, among others. The panel comprised of Prof Ramakrishna Head- IPR Research

Centre, National Law School, Bengaluru, Krishna Sarma Managing Partner, Corporate Law Group, Komal Kalha Sr Counsel, US Patent & Trademark Office, and Dr Rca Godbole Scientist and IP Advisor.

11. **Immune Pharma, Hadasit file joint patent on oral use of anti-eotaxin monoclonal antibodies including bertilimumab to treat GI & liver diseases** – Pharmabiz.com
    Biopharmaceutical company, Immune Pharmaceuticals Inc. (Immune), focused on the development of antibody-based therapeutics for the treatment of inflammatory diseases and cancer, and Hadasit, the technology transfer company of The Hadassah Medical Organization in Jerusalem, Israel, announced that they together filed a provisional patent on the oral use of anti-eotaxin monoclonal antibodies, including Immune's bertilimumab, for the treatment of inflammatory gastro-intestinal (GI) and liver diseases. Immune signed a licensing agreement with Hadasit in conjunction with the provisional patent filing. "Oral administration of a non-absorbable mouse anti-eotaxin-1 antibody showed biological activity in the gut, and exerted a systemic immuno-modulatory effect to alleviate immune-mediated hepatitis in an animal model. The data suggests that testing for eotaxin-1 serum levels, and using oral bertilimumab, a fully human monoclonal antibody, may enable the identification and treatment of patients with high-eotaxin-1-associated NASH," said Professor Yaron Ilan, Professor of Medicine, Gastro-Enterology and Liver Units and director, Department of Medicine at Hebrew University's Hadassah Hospital in Jerusalem, Israel, who conducted the research supporting the provisional patent application.

12. **Odisha government partners with Roche Diagnostics India under PPP mode to enable access to safe blood across the state** – OrissaDiary.com
    Govt. of Odisha announced the launch of the first-ever 'Roche NAT Solution' under Public Private Partnership with Roche Diagnostics (India) at Capital Hospital, Bhubaneswar. The Odisha State Health and Family Welfare, I & PR Minister, Hon. Shri. Atanu Sabyasachi Nayak inaugurated the NAT Blood Screening Project at Capital Hospital, Bhubaneshwar earlier today. Along with him are Odisha Tourism & Culture Minister, Hon Shri Ashok Chandra Panda and Hon. Dr. Prasanna Kumar Patasani, MP., Mr. Priyadarshi Mishra, Hon'ble MLA, Bijaya Kumar Mohanty, Hon'ble MLA, Mr. Ananta Narayan Jena, Mayor, BMC, Bhubaneswar, Mrs. Arti Ahuja, Principal Secretary, Health and Family Welfare, Niranjan Sahoo Collector, Khurda were present in this auspicious event.